Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Cardiac Neuromodulation for Heart Failure

NCT: NCT04573699 · COMPLETED

NCT IDNCT04573699
StatusCOMPLETED
Start Date2020-12-15
Completion2022-12-15
SponsorBackBeat Medical Inc (INDUSTRY)
First posted
Last updated

Brief Summary

This investigation will evaluate the ability of the Moderato® System to safely and effectively deliver CNT, to reduce sympathetic activity in heart failure patients

Frequently Asked Questions

What is Cardiac Neuromodulation for Heart Failure?

Cardiac Neuromodulation for Heart Failure is a clinical trial registered under NCT04573699. Current status: COMPLETED.

What is the status of NCT04573699?

The current status of NCT04573699 (Cardiac Neuromodulation for Heart Failure) is: COMPLETED.

When did Cardiac Neuromodulation for Heart Failure start?

Cardiac Neuromodulation for Heart Failure started on 2020-12-15.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑